---
title: "Strides Pharma Science Ltd (STAR) — Share Price, Financials & Analysis"
symbol: "STAR"
company: "Strides Pharma Science Ltd"
canonical: "https://tapetide.com/stocks/STAR"
isin: "INE939A01011"
nse_symbol: "STAR"
bse_code: "532531"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
market_cap_cr: 10969.47
generated_at: "2026-09-13T18:19:30.626Z"
---

# Strides Pharma Science Ltd (STAR)

Canonical page: https://tapetide.com/stocks/STAR

## Company

- **NSE Symbol:** STAR
- **BSE Code:** 532531
- **ISIN:** INE939A01011
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2000-02-02
- **CEO:** Mr. Arun Kumar Pillai B.Com.
- **Employees:** 3301
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** strides.com

## About

Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.[1] The company's pharmaceutical products are sold in over 100 countries.[2]
The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.[3]

## Latest Price

- **Price:** ₹1183.4
- **Change:** -33.6 (-2.76%)
- **Open:** ₹1199.9
- **Day High:** ₹1215.9
- **Day Low:** ₹1179
- **Previous Close:** ₹1217
- **Volume:** 161625
- **As Of:** 2026-09-11T10:24:52+00:00

## Key Fundamentals

Observed at 2026-09-11T04:43:19.185902Z.

- **Market Cap:** ₹10969.47 Cr
- **Classification:** Microcap
- **P/E (reported):** 17.7
- **P/E (TTM):** 17.78
- **EPS (TTM):** ₹66.56
- **Book Value:** ₹337.15
- **Price to Book:** 3.61
- **Dividend Yield:** 0.41%
- **ROE:** 18.24%
- **ROCE:** 21.01%
- **Debt to Equity:** 0.57
- **Revenue (yearly):** ₹5009.4 Cr
- **Net Income:** ₹574.5 Cr
- **EBITDA:** ₹1076 Cr
- **52-Week High:** ₹1231
- **52-Week Low:** ₹768.65
- **RSI (14):** 81.01

## Tapetide Score

- **Score:** 50 / 100
- **Score date:** 2026-09-04
- **Archetype:** No Dominant Pattern
- **What it means:** The three pillars do not combine into a recognisable pattern. Read them individually rather than looking for one story — the lack of a pattern is itself the finding.
- **Pillar profile:** Quality: Average · Valuation: Cheap · Momentum: Falling
- **Percentile:** 47.7 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 18.26 | 9% |
| growth | 29.73 | 9% |
| momentum | 49.54 | 12% |
| ownership | 58.01 | 24% |
| quality | 53.63 | 22% |
| valuation | 83.59 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has delivered good profit growth of 20.1% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 57.0%

### Weaknesses

- Stock is trading at 3.51 times its book value
- The company has delivered a poor sales growth of 7.94% over past five years.
- Promoters have pledged 38.1% of their holding.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 2.65% | 0.21% | 372.48% |
| ebitda margin growth | 22.11% | 15.3% | 35.69% | 515.47% |
| net income growth | 28% | 40.33% | 71% | 20% |
| revenue growth | 0.04% | 8.33% | 10% | 8% |
| roce | 26.66% | -1.27% | 275.85% | 6.77% |
| roe | 28.01% | 15.22% | 9.04% | -191.66% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 999 | 1006 | 1044 | 1054 | 1167 | 1154 | 1190 | 1120 | 1221 | 1195 | 1323 | 1265 |
| Expenses | 889 | 876 | 874 | 866 | 983 | 943 | 973 | 902 | 990 | 959 | 1084 | 1037 |
| Operating Profit | 111 | 129 | 169 | 188 | 184 | 210 | 218 | 218 | 231 | 236 | 240 | 228 |
| OPM % | 11 | 13 | 16 | 18 | 16 | 18 | 18 | 19 | 19 | 20 | 18 | 18 |
| Other Income | -129 | 60 | -27 | 3299 | 25 | 4 | -12 | 0 | 18 | 104 | 3 | 68 |
| Interest | 79 | 70 | 71 | 73 | 74 | 52 | 50 | 47 | 46 | 43 | 42 | 41 |
| Depreciation | 60 | 49 | 48 | 47 | 48 | 48 | 49 | 49 | 50 | 51 | 53 | 56 |
| Profit before tax | -157 | 70 | 23 | 3369 | 86 | 114 | 106 | 122 | 153 | 245 | 148 | 200 |
| Tax % | -5 | 23 | 55 | 1 | 16 | 21 | 20 | 13 | 14 | 15 | 13 | 17 |
| Net Profit | -149 | 54 | 10 | 3350 | 72 | 90 | 86 | 106 | 132 | 208 | 129 | 165 |
| EPS in Rs | -14.54 | 5.4 | 1.98 | 364.69 | 7.81 | 9.54 | 8.91 | 10.8 | 13.84 | 21.93 | 13.77 | 17.02 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 2845 | 2178 | 2752 | 3316 | 3070 | 3688 | 3890 | 4565 | 4859 | 5004 |
| Expenses | 2448 | 1982 | 2338 | 2779 | 3201 | 3544 | 3362 | 3763 | 3933 | 4070 |
| Operating Profit | 398 | 197 | 414 | 537 | -131 | 145 | 528 | 803 | 925 | 935 |
| OPM % | 14 | 9 | 15 | 16 | -4.3 | 3.9 | 14 | 18 | 19 | 19 |
| Other Income | 643 | 303 | -43 | 109 | -112 | 92 | -100 | 3313 | 124 | 193 |
| Interest | 196 | 79 | 156 | 150 | 177 | 261 | 280 | 249 | 179 | 172 |
| Depreciation | 154 | 117 | 174 | 206 | 233 | 243 | 214 | 192 | 202 | 210 |
| Profit before tax | 690 | 303 | 42 | 289 | -653 | -268 | -65 | 3675 | 669 | 746 |
| Tax % | 1 | -9 | 27 | 11 | -27 | -21 | 45 | 2 | 14 | — |
| Net Profit | 684 | 330 | 31 | 258 | -474 | -212 | -94 | 3598 | 575 | 634 |
| EPS in Rs | 74.25 | 36.27 | 4.06 | 29.93 | -51.25 | -22.44 | -7.68 | 389.75 | 60.34 | 66.56 |
| Dividend Payout % | 3 | 8 | 345 | 8 | 0 | -7 | -33 | 1 | 8 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 89 | 90 | 90 | 90 | 90 | 90 | 90 | 92 | 92 | 92 |
| Reserves | 2659 | 2374 | 2559 | 2438 | 2687 | 2269 | 2122 | 2034 | 2460 | 3015 |
| Borrowings | 3700 | 2520 | 3221 | 2235 | 2348 | 3025 | 3030 | 2517 | 1880 | 1758 |
| Other Liabilities | 1598 | 1601 | 1937 | 1369 | 1844 | 1556 | 1352 | 1157 | 1498 | 1941 |
| Total Liabilities | 8046 | 6585 | 7807 | 6131 | 6969 | 6940 | 6594 | 5799 | 5929 | 6807 |
| Fixed Assets | 2980 | 2977 | 3648 | 2099 | 2219 | 2347 | 2311 | 1865 | 1899 | 2101 |
| CWIP | 780 | 620 | 453 | 413 | 447 | 291 | 151 | 162 | 207 | 447 |
| Investments | 1525 | 588 | 702 | 549 | 697 | 540 | 490 | 303 | 409 | 291 |
| Other Assets | 2762 | 2400 | 3005 | 3070 | 3605 | 3762 | 3642 | 3470 | 3414 | 3967 |
| Total Assets | 8046 | 6585 | 7807 | 6131 | 6969 | 6940 | 6594 | 5799 | 5929 | 6807 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 288 | 187 | 60 | 205 | 481 | -258 | 44 | 701 | 684 | 703 |
| Cash from Investing Activity | -1222 | 570 | -145 | 1321 | -522 | -119 | 302 | -150 | -90 | -173 |
| Cash from Financing Activity | 338 | -1016 | 194 | -1709 | -16 | 421 | -214 | -693 | -643 | -453 |
| Net Cash Flow | -596 | -259 | 110 | -184 | -56 | 45 | 133 | -142 | -48 | 76 |
| Free Cash Flow | -386 | -212 | -256 | 58 | 188 | -326 | -43 | 672 | 505 | 291 |
| CFO/OP | 66 | 61 | 59 | 60 | 60 | 199 | -30 | 128 | 77 | 84 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 132 | 113 | 165 | 124 | 122 | 144 | 129 | 107 | 96 | 97 |
| Inventory Days | 209 | 146 | 294 | 254 | 329 | 285 | 257 | 235 | 236 | 305 |
| Days Payable | 221 | 188 | 299 | 259 | 323 | 260 | 220 | 178 | 190 | 244 |
| Cash Conversion Cycle | 120 | 71 | 160 | 119 | 128 | 168 | 165 | 164 | 141 | 157 |
| Working Capital Days | -122 | -4 | -70 | -70 | -22 | -28 | -11 | -19 | 24 | 38 |
| ROCE % | 11 | 16 | 2 | 5 | 8 | -5 | 0 | 7 | 15 | 18 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 27.78% | 27.39% | 25.88% | 25.86% | 25.84% | 26.82% | 28.3% | 28.3% | 27.86% | 27.86% | 27.91% | 27.91% |
| FIIs | 17.25% | 19.45% | 24.57% | 26.71% | 30.08% | 28.48% | 28.32% | 28.02% | 28.51% | 29.52% | 28.68% | 28.39% |
| DIIs | 18.22% | 17.56% | 17.66% | 18.18% | 18.24% | 16.92% | 13.72% | 13.3% | 12.98% | 13.02% | 14.45% | 15.41% |
| Government | 0.01% | 0.01% | 0.39% | 0.39% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 23.39% | 22.65% | 21.19% | 20.87% | 18.57% | 20.86% | 21.52% | 22.1% | 22.44% | 21.42% | 20.78% | 20.42% |
| Others | 13.35% | 12.94% | 10.32% | 8% | 7.26% | 6.9% | 8.14% | 8.27% | 8.2% | 8.17% | 8.17% | 7.85% |
| No. of Shareholders | 101638 | 91182 | 84695 | 91917 | 96009 | 114236 | 95125 | 92889 | 91206 | 85589 | 86616 | 94856 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 13 / 3 / 3

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 1117.25 | Buy |
| EMA (10) | 1132.19 | Buy |
| SMA (20) | 1050.57 | Buy |
| EMA (20) | 1085.87 | Buy |
| SMA (50) | 1044.44 | Buy |
| EMA (50) | 1056.84 | Buy |
| SMA (100) | 1070.8 | Buy |
| EMA (100) | 1039.77 | Buy |
| SMA (200) | 985.87 | Buy |
| EMA (200) | 990.27 | Buy |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 71.35 | Sell |
| MACD (12,26,9) | 45.93 | Buy |
| Stochastic (14,3,3) | 90.97 | Sell |
| ADX (14) | 35.12 | Buy |
| Williams %R (14) | -16.03 | Sell |
| ATR (14) | 42.98 | High Volatility |
| ROC (12) | 20.4 | Buy |
| Stoch RSI (14) | 74.05 | Neutral |
| UO (7,14,28) | 67.71 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 1 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |

Based on 1 analyst ratings, observed at 2026-09-11T04:43:20.697294+00:00.

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 8h - Earnings Call to discuss the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 8h - Earnings Call to discuss the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/7981bf3f-18f6-4eb1-b5f0-028a767e2b40.pdf) |
| 5 Feb - USFDA EIR closes Chestnut Ridge inspection (Dec 17–23, 2025), classified VAI; supports nasal spray pre-approval. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 5 Feb - USFDA EIR closes Chestnut Ridge inspection (Dec 17–23, 2025), classified VAI; supports nasal spray pre-approval.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f9e8191a-4aa7-470b-88b3-ab4f0f7db8cc.pdf) |
| 5 Feb - USFDA closed Chestnut Ridge inspection (Dec 17-23, 2025) as VAI; covered drug-device nasal sprays. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised) 5 Feb - USFDA closed Chestnut Ridge inspection (Dec 17-23, 2025) as VAI; covered drug-device nasal sprays.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/258bbc32-e404-4002-894b-82ba273a4c59.pdf) |
| 4 Feb - Strides to meet investors at Manthan Systematix on Feb 10, 2026 to discuss Q3 FY26 earnings presentation. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 4 Feb - Strides to meet investors at Manthan Systematix on Feb 10, 2026 to discuss Q3 FY26 earnings presentation.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7ced99df-34a6-40a9-83b5-2b56b7e6bbfc.pdf) |
| 3 Feb - Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025. | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript 3 Feb - Transcript of earnings call pertaining to unaudited financial results of the Company for the quarter and nine months ended December 31, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cc699e4f-05b6-40ff-90e4-86189ee75d00.pdf) |
| 25 Mar - Trading window closed Apr 1, 2026 until 48 hours after Q4 FY2026 results; board meeting date TBA. | [Closure of Trading Window 25 Mar - Trading window closed Apr 1, 2026 until 48 hours after Q4 FY2026 results; board meeting date TBA.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c73ed8cc-4d28-45d6-905f-bbe890953d57.pdf) |
| 2 Apr - Certificate As per Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018, for the quarter ended March 31, 2026 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 2 Apr - Certificate As per Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018, for the quarter ended March 31, 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f29ea30a-3fc5-49fa-b7ba-fe8369d2027e.pdf) |
| 17 Mar - Strides to acquire Sandoz branded generics in SSA for US$12m; deal doubles Africa presence; close by Q2 FY27. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 17 Mar - Strides to acquire Sandoz branded generics in SSA for US$12m; deal doubles Africa presence; close by Q2 FY27.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/96378031-de7d-43aa-ade0-f90ab616fef1.pdf) |
| 17 Mar - Strides acquires multiple Sandoz generic brands in SSA; USD12M upfront, royalties; expected close by Sept 30, 2026. | [Disclosure Under Regulation 30 Of SEBI Listing Regulations 17 Mar - Strides acquires multiple Sandoz generic brands in SSA; USD12M upfront, royalties; expected close by Sept 30, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9a806890-365e-4083-8d48-ed686ac56a23.pdf) |
| 17 Feb - Arco Lab acquired remaining 50% of Neviton for €2m (~Rs21.77cr), effective Feb 16, 2026. | [Announcement under Regulation 30 (LODR)-Updates on Acquisition 17 Feb - Arco Lab acquired remaining 50% of Neviton for €2m (~Rs21.77cr), effective Feb 16, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/69f14d63-fc2c-4bf2-b77c-ccdf60277768.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-08-19 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=882ed383-d260-470a-8a39-901dbe40c9f7.pdf) |
| 2026-08-18 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=679dbd0f-714f-466d-bbfa-8a5042c21b44.pdf) |
| 2026-08-14 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2a2333af-6bca-4615-b78f-d0ec592d8212.pdf) |
| 2026-08-03 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8a9830c8-2a01-4753-9790-8b3b04244b4d.pdf) |
| 2026-08-01 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=92be363e-4f85-40be-b7d2-edb9c1cfcbd6.pdf) |
| 2026-07-31 | [Announcement under Regulation 30 (LODR)-Press Release / Media Release](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=acf9235f-5b6a-4e15-9657-1381616e905c.pdf) |
| 2026-07-24 | [Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended June 30 2026 Amongst Other Matters.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0d008ad3-22d5-4ad5-b269-d2365b03ac59.pdf) |
| 2026-07-24 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=be9de3f3-2b98-4cd8-ae9a-b209887b9661.pdf) |
| 2026-07-21 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9034cd74-11a8-4022-b264-1470d9c31d9f.pdf) |
| 2026-07-21 | [Notice Of 35Th Annual General Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5033378f-27b6-4ac0-95c8-fc5d19e0daaa.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-07-31 | [Outcome Of Board Meeting Of The Company Held On July 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=78f07ce7-58c4-4b15-9537-2703841614dd.pdf) |
| 2026-05-18 | [Outcome Of Board Meeting Of The Company Held On May 18 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3c60873-2c29-4645-b0e9-ec1895686ba7.pdf) |
| 2026-01-30 | [Un-Audited Financial Results (Consolidated & Standalone) For The Quarter And Nine Months Ended December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8b2f87ed-dcea-451f-ab08-edef5b9f5709.pdf) |
| 2025-10-31 | [Outcome Of Board Meeting - Un-Audited Financial Results (Consolidated & Standalone) For The Quarter And Half Year Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ab75eac0-a270-452f-8dbe-111914b96f17.pdf) |
| 2025-07-29 | [Financial Results (Consolidated & Standalone) For The Quarter Ended June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=33ebd29e-37e3-4ccf-a60a-57710ecbdd0b.pdf) |
| 2025-05-22 | [Outcome Of Board Meeting Of The Company Held On May 22 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b30c80ec-3405-467c-903a-716f508a8306.pdf) |
| 2025-01-30 | [Outcome Of Board Meeting - Un-Audited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1c7fb38e-4d7b-4cf0-ba27-66648bac5e65.pdf) |
| 2024-10-24 | [Outcome Of Board Meeting - Un-Audited Financial Results (Standalone & Consolidated) For Quarter And Half-Year Ended September 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=342ea0a4-93f8-4caf-a592-b6e368b9f9de.pdf) |
| 2024-07-29 | [Outcome Of Board Meeting - Un-Audited Financial Results (Standalone & Consolidated) For Quarter Ended June 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e79339fc-b780-4534-8aea-c180814ad730.pdf) |
| 2024-05-22 | [Outcome Of Board Meeting - May 22, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=416d7b90-0799-4297-bf31-4e2d5c685010.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-07-31 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5c454bf8-5387-4dee-91d5-220cf0681c0a.pdf) |
| 2026-05-18 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=95644219-f3e7-41a4-8bdd-1786aa63f5fd.pdf) |
| 2026-01-30 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3ada5c53-065b-4cf6-a49a-8e35f2171226.pdf) |
| 2024-02-02 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fe3ada58-ceee-4d6f-a372-390e314b16a7.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-07-31 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b766f83b-9895-43d2-b0f4-c400fbb48db4.pdf) |
| 2026-05-18 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1875b2ac-11d0-4672-a2ba-4c751f3a3159.pdf) |
| 2026-01-30 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6e6853af-1a57-4bb8-964f-8b9fb7bc8010.pdf) |
| 2025-10-31 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ebb37d52-a27e-4beb-8f15-1f1b2f5e966e.pdf) |
| 2025-07-29 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f34981f1-c07a-4bcf-b5e6-231a4daae171.pdf) |
| 2025-05-22 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b72086bc-8a4e-436c-b5e3-f4f980a236d5.pdf) |
| 2024-10-24 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=022c4317-c8c1-4f4a-a328-989f03fbc9fd.pdf) |
| 2023-10-30 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d201d823-a062-4706-a9fb-a53efd23721b.pdf) |
| 2023-09-25 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4c7fb29e-ebef-499a-a2f8-0ce949df018b.pdf) |
| 2023-08-02 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=28a81972-fd9b-4bf4-8938-b05452aceab2.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-05-21 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7147ef9f-bea3-419e-a8cf-c18af047bfce.pdf) |
| 2026-02-03 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cc699e4f-05b6-40ff-90e4-86189ee75d00.pdf) |
| 2023-06-01 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f6d49081-0415-4964-8893-1c31ae04c654.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Oct 2024 | [Concall - Oct 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5f3d350e-e9b9-41a3-96ce-a21a51d77b3e.pdf) |
| Oct 2024 | [Concall - Oct 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=432ef4b9-4063-41ee-b37e-598a22ab489f.pdf) |
| Oct 2024 | [Concall - Oct 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5f3d350e-e9b9-41a3-96ce-a21a51d77b3e.pdf) |
| Oct 2024 | [Concall - Oct 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/432ef4b9-4063-41ee-b37e-598a22ab489f.pdf) |
| Oct 2023 | [Concall - Oct 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b9b95a97-0bd9-44c8-94ea-cf40759e821d.pdf) |
| Oct 2023 | [Concall - Oct 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b9b95a97-0bd9-44c8-94ea-cf40759e821d.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bb389025-5ce3-44c1-8940-cfd76882df76.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bb389025-5ce3-44c1-8940-cfd76882df76.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ae220251-3a15-4d0c-8e95-b004dbd3c98c.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ae220251-3a15-4d0c-8e95-b004dbd3c98c.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2012 from nse](https://archives.nseindia.com/annual_reports/AR_71_STAR_2012_2012_10062013173708.zip) |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9034cd74-11a8-4022-b264-1470d9c31d9f.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7591369b-b3bf-458a-9e6e-710f89f6bd4b.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f3fef37a-74ee-491f-87fe-2e2cc48005a0.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2849f7f9-46e1-4ecb-a836-986717170dcb.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/532531/74399532531.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/532531/69463532531.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/532531/5325310320.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/532531/5325310319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/532531/5325310318.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:19:30.626Z.